Basic Information
| LncRNA/CircRNA Name | GAS5 |
| Synonyms | NA |
| Region | GRCh38_1:173863900-173868882 |
| Ensemble | ENSG00000234741 |
| Refseq | NR_002578 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | RT-PCR, Western blot |
| Sample | breast cancer tissues and cells |
| Expression Pattern | down-regulated |
| Function Description | Overexpression of GAS5 significantly enhanced the ADR sensitivity and apoptosis, and it inhibited the efflux function and expression of ABCB1 in vitro, GAS5 acted as an endogenous ??ponge??by competing for miR-221-3p binding to regulate its target dickkopf 2 (DKK2), and then it inhibited the activation of the Wnt/b-catenin pathway. |
| Pubmed ID | 32160712 |
| Year | 2020 |
| Title | The lncRNA-GAS5/miR-221-3p/DKK2 Axis Modulates ABCB1-Mediated Adriamycin Resistance of Breast Cancer via the Wnt/b-Catenin Signaling Pathway |
External Links
| Links for GAS5 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |